Leaflet DABIGATRAN ETEXILAT VIATRIS 75mg capsules
Indicated for: prevention and treatment of thromboembolism
Route of administration: oral
Substance: dabigatran etexilat (anticoagulant)
ATC: B01AE07 (Blood and blood forming organs | Antithrombotic agents | Direct thrombin inhibitors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Dabigatran etexilate is an oral anticoagulant used for the prevention and treatment of blood clots. It is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Dabigatran etexilate works as a direct thrombin inhibitor, preventing the formation of blood clots. It is administered orally in capsule form, with the dosage adjusted based on the patient's condition and bleeding risk.
Side effects may include bleeding (nasal, gastrointestinal, or other types), dyspepsia (heartburn), nausea, or allergic reactions. It is contraindicated in patients with active bleeding, severe renal impairment, or hypersensitivity to the substance. It should also be used cautiously in patients with a high risk of bleeding.
General data about DABIGATRAN ETEXILAT VIATRIS 75mg
- Substance: dabigatran etexilat
- Date of last drug list: 01-05-2024
- Commercial code: W70192001
- Concentration: 75mg
- Pharmaceutical form: capsules
- Quantity: 10
- Product type: generic
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for dabigatran etexilat
Concentrations available for dabigatran etexilat
- 110mg
- 150mg
- 20mg
- 30mg
- 40mg
- 50mg
- 6.25mg/ml
- 75mg